Innovent And Lilly’s Rituximab Candidate Accepted By China’s NMPA
A new drug application for IBI301, a rituximab biosimilar candidate co-developed by Innovent and Eli Lilly, has been accepted by China’s NMPA.
A new drug application for IBI301, a rituximab biosimilar candidate co-developed by Innovent and Eli Lilly, has been accepted by China’s NMPA.